Shockwave C2 Aero Delivers. Our next-gen Coronary IVL device is engineered based on your feedback — and is ready to help you safely and effectively crack calcium with our proven mechanism of action (MOA).
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Brian C. Case, MD; Bailey Ann Richardson, MSN, AGNP, RN-BC, RNFA, CNOR, RCIS
Bailey Richardson, MSN, speaks with Brian Case, MD, about coronary microvascular dysfunction and why “normal” angiography can miss the cause of symptoms in patients with angina with non-obstructive coronary arteries (ANOCA).
Bailey Richardson, MSN, speaks with Brian Case, MD, about coronary microvascular dysfunction and why “normal” angiography can miss the cause of symptoms in patients with angina with non-obstructive coronary arteries (ANOCA).
In this 29-minute video (chapters available), Matthew H. Gonzalez, MD, discusses how pulmonary artery pressure monitoring with the CardioMEMS™ HF System made by Abbott shifts management from reactive to proactive by detecting hemodynamic...
In this 29-minute video (chapters available), Matthew H. Gonzalez, MD, discusses how pulmonary artery pressure monitoring with the CardioMEMS™ HF System made by Abbott shifts management from reactive to proactive by detecting hemodynamic...
Dr. Tanvir Bajwa highlights how the Stedi Extra Support Guidewire from Medtronic is designed to improve tracking, stability, and coaxial deployment during TAVR, and shares early experience suggesting it can support more predictable implant...
Dr. Tanvir Bajwa highlights how the Stedi Extra Support Guidewire from Medtronic is designed to improve tracking, stability, and coaxial deployment during TAVR, and shares early experience suggesting it can support more predictable implant...
Market tends are showing that more procedures are moving to out-of-hospital care settings, such as ambulatory surgery centers (ASCs) and office-based labs (OBLs) due to financial and operational benefits to the healthcare system and desire to...
Market tends are showing that more procedures are moving to out-of-hospital care settings, such as ambulatory surgery centers (ASCs) and office-based labs (OBLs) due to financial and operational benefits to the healthcare system and desire to...
In this video, Ryan K. Kaple, MD, FACC, FSCAI, discusses how the CardioMEMS™ HF System has become an essential tool in managing patients with chronic heart failure.
In this video, Ryan K. Kaple, MD, FACC, FSCAI, discusses how the CardioMEMS™ HF System has become an essential tool in managing patients with chronic heart failure.
Bailey Ann Richardson, MSN, AGNP, RN-BC, RNFA, CNOR, RCIS; Morton J. Kern, MD, MSCAI, FACC, FAHA; Arnold H. Seto, MD, MPA, CCDS, FACC, FSCAI
A discussion of the study presented at SCAI's 2025 Annual Meeting, " Percutaneous Coronary Intervention in Ambulatory Surgery Centers: Procedural Volume Trends and Outcomes in the Medicare Population".
A discussion of the study presented at SCAI's 2025 Annual Meeting, " Percutaneous Coronary Intervention in Ambulatory Surgery Centers: Procedural Volume Trends and Outcomes in the Medicare Population".
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
The Optiq AI imaging chain common to all six systems uses AI to analyze and optimize image data in real time. The six new systems address a wide range of clinical uses, operational needs, and financial considerations.
The Optiq AI imaging chain common to all six systems uses AI to analyze and optimize image data in real time. The six new systems address a wide range of clinical uses, operational needs, and financial considerations.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
Patients with the ‘lemon-on-sticks’ phenotype (low BMI/high WHR) showed the strongest signs of congestion, had the highest concentrations of the heart strain biomarker, N-terminal pro-B-type natriuretic peptide, and presented with a...
Patients with the ‘lemon-on-sticks’ phenotype (low BMI/high WHR) showed the strongest signs of congestion, had the highest concentrations of the heart strain biomarker, N-terminal pro-B-type natriuretic peptide, and presented with a...
“We have demonstrated that robotic assistance can be safely and reliably applied to the full spectrum of coronary lesion complexity, including the most challenging anatomies," said Dr. Mohammed Nejjari.
“We have demonstrated that robotic assistance can be safely and reliably applied to the full spectrum of coronary lesion complexity, including the most challenging anatomies," said Dr. Mohammed Nejjari.
- First co-registered and co-aligned IVUS-OCT Platform for Intravascular Imaging
- Company Positioned for U.S. Commercial Launch in a Growing Intravascular Imaging Market Estimated at Over $1 Billion
TORONTO-- Conavi Medical Corp.,...
- First co-registered and co-aligned IVUS-OCT Platform for Intravascular Imaging
- Company Positioned for U.S. Commercial Launch in a Growing Intravascular Imaging Market Estimated at Over $1 Billion
TORONTO-- Conavi Medical Corp.,...
The COMMENCE trial provides prospective, 10-year data demonstrating the durability of Edwards’ RESILIA tissue and its role in lifetime management for patients with aortic stenosis.
The COMMENCE trial provides prospective, 10-year data demonstrating the durability of Edwards’ RESILIA tissue and its role in lifetime management for patients with aortic stenosis.
By integrating the world’s smallest electrical impedance sensor with predictive algorithms into a standard 0.014” guidewire, the Clotild clot-sensing guidewire is designed to provide physicians with real-time, in situ biological intelligence...
By integrating the world’s smallest electrical impedance sensor with predictive algorithms into a standard 0.014” guidewire, the Clotild clot-sensing guidewire is designed to provide physicians with real-time, in situ biological intelligence...
SOUTH SAN FRANCISCO, Calif. -- Cytokinetics, Incorporated announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3...
SOUTH SAN FRANCISCO, Calif. -- Cytokinetics, Incorporated announced positive topline results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3...
Chicago, IL – Johnson & Johnson announced results from a novel U.S. pilot single-arm trial that evaluated the safety and feasibility of planned Impella 5.5™ support in adult patients undergoing cardiac surgery in the setting of...
Chicago, IL – Johnson & Johnson announced results from a novel U.S. pilot single-arm trial that evaluated the safety and feasibility of planned Impella 5.5™ support in adult patients undergoing cardiac surgery in the setting of...
Chicago, IL – Johnson &...
05/05/2026
Cath Lab Digest
About Shockwave
Shockwave IVL pioneers innovative technologies that help improve lives around the globe. The Shockwave IVL system is transforming standards of care and driving better outcomes for underserved patients. Shockwave IVL: In the U.S.: Rx only. Prior to use, please reference the Important Safety Information for more information on indications, contraindications, warnings, precautions and adverse events.